George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Well the other company they just brought is in Bedfordshire and Cambridgeshire is next door , with their concern for global warming makes sense to buy company’s next to each other for the days you check the books, cut the amount of travel hahaha
Pfizer raised the price of its Covid-19 vaccine by more than a quarter and Moderna by more than a tenth in the latest EU supply contracts as Europe battled supply disruptions and concerns about side effects from rival products.
The groups are set to generate tens of billions of dollars in revenue this year as they sign new deals with countries anxious to secure supplies for potential booster shots in the face of the spread of the highly infectious Delta coronavirus variant.
The terms of the deals, struck this year for a total of up to 2.1bn shots until 2023, were renegotiated after phase 3 trial data showed their messenger ribonucleic acid vaccines had higher efficacy rates than cheaper shots developed by Oxford/AstraZeneca and Johnson & Johnson.
The new price for a Pfizer shot was €19.50 against €15.50 previously, according to portions of the contracts seen by the Financial Times.
The price of a Moderna jab was $25.50 a dose, the contracts show, up from what people familiar with the matter said was about €19 ($22.60) in the first procurement deal but lower than a previously agreed $28.50 because the order had grown, according to one official close to the negotiations.
The official said the companies had capitalised on their market power and deployed the “usual pharma rhetoric?.?.?.?Vaccines work so they increased the ‘value’.”
Pfizer last week raised its guidance for annual vaccine revenue by nearly a third to $33.5bn, after sales of the shot helped almost double sales in the second quarter.
Chief executive Albert Bourla said prices for higher-income countries were “comparable”, with middle-income countries charged about half and lower-income countries paying cost.
Pfizer, which shares profits with its German partner BioNTech, expects to raise prices after the pandemic is over.
The revenue gap between messenger RNA vaccines, whose genetic instructions prompt cells to make viral proteins that prime the immune system, and more traditional rivals that contain either viral proteins or an inactivated virus, is set to widen further next year according to forecasts compiled for the FT by Airfinity.
The life sciences consultancy predicts sales of Pfizer’s shot will hit $56bn with Moderna’s reaching $30bn, as they dominate the high-income markets.
https://www.ft.com/content/d415a01e-d065-44a9-bad4-f9235aa04c1a
I think I’m modest with 2.25p maybe it could double that, but can anybody genuinely believe it could pass even £10 let alone hit 45 , don’t get me wrong I ****ing hope it could and will , but big pharmaceutical share price isn’t even that
Anyway fingers crossed